ERISA Ledger · U.S. DOL EBSA Form 5500 (2024)

Kiniksa Pharmaceuticals CORP.

Official 2024 U.S. DOL Form 5500 summary for Kiniksa Pharmaceuticals CORP. (Kiniksa Pharmaceuticals 401(k) Plan · EIN 47-4596717 · PN 001): $37.17M net assets, 305 active participants, and $21.15 per $10,000 (21.15 bps).

Reported Form 5500 Fee & Service Summary

Plan SponsorKiniksa Pharmaceuticals CORP.
Filing IdentifierKiniksa Pharmaceuticals 401(k) Plan · EIN 47-4596717 · PN 001
Plan Category & State401(k) Defined Contribution (MA)
Asset-Size Peer Cohort$25M-$100M
Plan Net Assets (2024)$37.17M
Active Participants305
Direct Admin Fee Rate$21.15 per $10,000 (21.15 bps)
Cohort Peer Median$19.23 per $10,000 (19.23 bps)
Primary Recordkeeper / ProviderFidelity Investments
Schedule H Line 4a RemittanceTimely Employer Remittance (0 reported on Line 4a)

Browse all 78,373 plans & Schedule C vendors · Methodology · Meru AI